Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation

Annals of the New York Academy of Sciences

Volumn 1160, Issue , 2009, Pages 294-299

  Samuel, Chrishan S ^a   Mookerjee, Ishanee ^a   Halls, Michelle L ^b   Summers, Roger J ^b   Chew, Elaine ^a   Bathgate, Ross A D ^a   Tregear, Geoffrey W ^a   Hewitson, Tim D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cell signaling; Myofibroblast; Relaxin; Transforming growth factor 1; Tubulointerstitial fibrosis; smooth muscle actin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; RECOMBINANT H2 RELAXIN; RECOMBINANT PROTEIN; RELAXIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL DIFFERENTIATION; CONFERENCE PAPER; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; KIDNEY CELL; MECHANICAL STRESS; MYOFIBROBLAST; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 64549156507     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03823.x     Document Type: Conference Paper

References (34)

1. Wynn, T.A. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117: 524-529.
2. Darby, I.A. & T.D. Hewitson. 2007. Fibroblast differentiation in wound healing and fibrosis. Int. Rev. Cytol. 257: 143-179.
3. Eddy, A.A. 2005. Progression in chronic kidney disease. Adv. Chronic Kidney Dis. 12: 353-365.
4. Samuel, C.S. & T.D. Hewitson. 2006. Relaxin in cardiovascular and renal disease. Kidney Int. 69: 1498-1502.
5. Samuel, C.S., T.D. Hewitson, E.N. Unemori, et al. 2007. Drugs of the future: The hormone relaxin. Cell. Mol. Life Sci. 64: 1539-1557.
6. Hewitson, T.D., I. Mookerjee, R. Masterson, et al. 2007. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 148: 660-669.
7. Bennett, R.G., K.K. Kharbanda & D.J. Tuma. 2003. Inhibition of markers of hepatic stellate cell activation by the hormone relaxin. Biochem. Pharmacol. 66: 867-874. 8.
8. Samuel, C.S., E.N. Unemori, I. Mookerjee, et al. 2004. Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145: 4125-4133.
9. Masterson, R., T.D. Hewitson, K. Kelynack, et al. 2004. Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol. Dial. Transplant. 19: 544-552.
10. Heeg, M.H., M.J. Koziolek, R. Vasko, et al. 2005. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 68: 96-109.
11. Hayashida, T., M. Decaestecker & H.W. Schnaper. 2003. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEBJ. 17: 1576-1578.
12. Poncelet, A.C., M.P. de Caestecker & H.W. Schnaper. 1999. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int. 56:1354-1365.
13. Halls, M.L., R.A. Bathgate & R.J. Summers. 2006. Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms. Mol. Pharmacol. 70: 214-226.
14. Dessauer, C.W. & B.T. Nguyen. 2005. Relaxin stimulates multiple signaling pathways: Activation of cAMP, PI3K, and PKCζ in THP-1 cells. Ann. N. Y. Acad. Sci. 1041: 272-279.
15. Winbanks, C.E., L. Grimwood, A. Gasser, et al. 2007. Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation. Int. J. Biochem. Cell. Biol. 39: 206-219.
16. Zhang, Q., S.H. Liu, M. Erikson, et al. 2002. Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J. Cell. Biochem. 85: 536-544.
17. Dschietzig, T., C. Bartsch, T. Kinkel, et al. 2005. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann. N. Y. Acad. Sci. 1041: 441-443.
18. Dschietzig, T., C. Bartsch, C. Richter, et al. 2003. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB. Circ. Res. 92: 32-40.
19. Nistri, S., M. Bigazzi & D. Bani. 2007. Relaxin as a cardiovascular hormone: Physiology, pathophysiology and therapeutic promises. Cardiovasc. Hematol. Agents Med. Chem. 5: 101-108.
20. Jeyabalan, A., S.G. Shroff, J. Novak, et al. 2007. The vascular actions of relaxin. Adv. Exp. Med. Biol. 612: 65-87.
21. Masini, E., S. Nistri, A. Vannacci, et al. 2004. Relaxin inhibits the activation of human neutrophils: Involvement of the nitric oxide pathway. Endocrinology 145: 1106-1112.
22. Bani, D., S. Nistri, P.F. Mannaioni, et al. 2006. Cardiac anaphylaxis: Pathophysiology and therapeutic perspectives. Curr. Allergy Asthma Rep. 6: 14-19.
23. Samuel, C.S., X.J. Du, R.A.D. Bathgate, et al. 2006. 'Relaxin' the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol. Ther. 112: 529-552.
24. Bani, D., M.C. Baccari, S. Quattrone, et al. 2002. Relaxin depresses small bowel motility through a nitric oxide-mediated mechanism. Studies in mice. Biol. Reprod. 66: 778-784.
25. Baccari, M.C., S. Nistri, M.G. Vannucchi, et al. 2007. Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R662-R668.
26. Shi, L., S.Q. Shi, G.R. Saade, et al. 2000. Studies of cervical ripening in pregnant rats: Effects of various treatments. Mol. Hum. Reprod. 6: 382-389.
27. Bani, D., S. Nistri, L. Cinci, et al. 2007. A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation. Regul. Pept. 144: 10-16.
28. Ho, T.Y., W. Yan & C.A. Bagnell. 2007. Relaxininduced matrix metalloproteinase-9 expression is associated with activation of the NF-κB pathway in human THP-1 cells. J. Leukoc. Biol. 81: 1303-1310.
29. Nistri, S. & D. Bani. 2003. Relaxin receptors and nitric oxide synthases: Search for the missing link. Reprod. Biol. Endocrinol. 1: 5.
30. Hsu, S.Y., K. Nakabayashi, S. Nishi, et al. 2002. Activation of orphan receptors by the hormone relaxin. Science 295: 671-674.
31. Samuel, C.S., C. Zhao, C.P. Bond, et al. 2004. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int. 65: 2054-2064.
32. Bathgate, R.A., R. Ivell, B.M. Sanborn, et al. 2006. International Union of Pharmacology: Recommendations for the nomenclature of receptors for relaxin family pep tides. Pharmacol. Rev. 58: 7-31.
33. Dschietzig, T., C. Bartsch, V. Stangl, et al. 2004. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEBJ. 18: 1536-1538.
34. Halls, M.L., E.T. Van Der Westhuizen, R.A. Bathgate, et al. 2007. Relaxin family peptide receptors: Former orphans reunite with their parent ligands to activate multiple signalling pathways. Br. J. Pharmacol. 150: 677-691.